{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:05:58Z","timestamp":1784786758648,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary cutaneous apocrine carcinoma (PCAC) is a rare malignant adnexal tumor with substantial diagnostic complexity and no established systemic therapy standard for advanced disease.Evidence for endocrine therapy, targeted therapy, and immune checkpoint inhibitors is limited to small series and case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A patient presented with a pruritic erythematous plaque on the left chest wall that progressively enlarged over one year. Skin biopsy and subsequent pathology consultation demonstrated invasive adenocarcinoma involving the dermis and subcutaneous tissue. Immunohistochemistry supported PCAC (CK7+, GATA3+, AR strongly positive, and patchy GCDFP-15 positivity), and a left axillary lymph node confirmed metastatic carcinoma. Whole-body\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT revealed extensive metastatic disease involving multiple lymph node stations, lung, pleura, and multiple bones, precluding upfront surgery. The patient received systemic therapy with serplulimab (300 mg intravenously every 3 weeks) plus anlotinib (10 mg orally once daily, days 1\u201314 of a 21-day cycle) and concomitant bicalutamide (50 mg orally once daily). After two cycles, CT imaging showed partial reduction in pulmonary nodules and mediastinal lymphadenopathy, with thinning of the chest wall lesion and resolution of a small pleural effusion. Subsequent follow-up demonstrated continued clinical improvement of the chest wall lesion and sustained radiological disease control, without new rapidly progressive visceral lesions. No clinically significant adverse events or notable laboratory toxicities were observed during treatment and follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates a feasible combination approach for widely metastatic PCAC using PD-1 blockade, anti-angiogenic therapy, and anti-androgen treatment, with clinical and radiographic improvement and favorable tolerability during follow-up. Prospective data are needed to clarify patient selection and define optimal systemic strategies for advanced PCAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1802283","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:38:46Z","timestamp":1784785126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-1 blockade combined with anlotinib and bicalutamide for metastatic primary cutaneous apocrine carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuqi","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Clinical Research Center for Cancer","place":["Hangzhou, China"]},{"name":"Cancer Center of Zhejiang University","place":["Hangzhou, China"]},{"name":"Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglin","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]},{"name":"Zhejiang Provincial Clinical Research Center for Cancer","place":["Hangzhou, China"]},{"name":"Cancer Center of Zhejiang University","place":["Hangzhou, China"]},{"name":"Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181590ba4","article-title":"Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases","volume":"32","author":"Robson","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.09.007","article-title":"Cutaneous and mammary apocrine carcinomas have different immunoprofiles","volume":"45","author":"Piris","year":"2014","journal-title":"Hum Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jso.22023","article-title":"Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, and optimal therapy for a rare neoplasm","volume":"105","author":"Hollowell","year":"2012","journal-title":"J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061204","article-title":"Immunoprofiles and oncologic outcomes of 15 patients with androgen receptor-positive salivary duct carcinoma","volume":"16","author":"Gogineni","year":"2024","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047290","article-title":"Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses","volume":"7","author":"Le","year":"2012","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3434","article-title":"Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy\u2014a case report","volume":"8","author":"Collette","year":"2020","journal-title":"Clin Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/his.14809","article-title":"Poorly differentiated cutaneous apocrine carcinomas: histopathological clues and immunohistochemical analysis for the diagnosis of this unusual neoplasm","volume":"82","author":"Plaza","year":"2023","journal-title":"Histopathology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3282","article-title":"Metastatic cutaneous apocrine carcinoma: a multidisciplinary approach incorporating endocrine therapy","volume":"28","author":"Ogata","year":"2018","journal-title":"Eur J Dermatol EJD"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115403","article-title":"Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas","volume":"222","author":"Dessinioti","year":"2025","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.11.008","article-title":"Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab","volume":"90","author":"Rogatsch","year":"2018","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s426590","article-title":"A retrospective study of anlotinib combined with anti-PD-1 inhibitors in the 2nd or later-line treatment of advanced solid tumors","volume":"16","author":"Li","year":"2023","journal-title":"Int J Gen Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.25259\/jcas_182_23","article-title":"Bicalutamide: a review","volume":"18","author":"Aulakh","year":"2025","journal-title":"J Cutan Aesthetic Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02001-3","article-title":"Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial","volume":"127","author":"Qin","year":"2022","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2507","article-title":"Metastatic cutaneous apocrine adenocarcinoma treated with a combination of pertuzumab-based targeted therapy and taxane chemotherapy: a case report","volume":"152","author":"Otsuka","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2025-268537","article-title":"Cutaneous curiosity: axillary apocrine carcinoma","volume":"18","author":"Singh","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1111\/1346-8138.17777","article-title":"Metastatic cutaneous apocrine adenocarcinoma successfully treated with nivolumab","volume":"52","author":"Murayama","year":"2025","journal-title":"J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/ddg.15652","article-title":"Complete response of a metastatic cutaneous apocrine carcinoma under oral S-1 monotherapy","volume":"23","author":"Ishizuki","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12877-024-05428-w","article-title":"Challenges in treating coexisting scrotal apocrine carcinoma and gastric cancer: insights from an elderly patient: a case report and literature review","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Geriatr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s13691-024-00700-7","article-title":"Treatment of HER2-positive cutaneous apocrine carcinoma of the axilla","volume":"13","author":"Kamata","year":"2024","journal-title":"Int Cancer Conf J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57859","article-title":"Primary cutaneous apocrine carcinoma of the thigh: a rare case report","volume":"16","author":"Bouabid","year":"2024","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1307647","DOI":"10.3389\/fsurg.2024.1307647","article-title":"Case Report: A challenging diagnosis of an apocrine sweat gland carcinoma","volume":"11","author":"Ahmad","year":"2024","journal-title":"Front Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s10147-023-02420-z","article-title":"Prognostic factors in cutaneous apocrine carcinoma: a single-institution retrospective study of 32 patients","volume":"28","author":"Tsuruta","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2340\/00015555-1354","article-title":"Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine","volume":"92","author":"Hidaka","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1200\/JCO.2009.26.1891","article-title":"Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy","volume":"28","author":"Tlemcani","year":"2010","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/030089160008600608","article-title":"Clinical management of a case of recurrent apocrine gland carcinoma of the scalp: efficacy of a chemotherapy schedule with methotrexate and bleomycin","volume":"86","author":"Morabito","year":"2000","journal-title":"Tumori"},{"key":"B30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/02844318909004511","article-title":"Apocrine carcinoma of the axillae. Case report","volume":"23","author":"Neumann","year":"1989","journal-title":"Scand J Plast Reconstr Surg Hand Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77444","article-title":"Aggressive primary cutaneous apocrine carcinoma of the scalp: A clinical case report","volume":"17","author":"Shaghaghian","year":"2025","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19930115)71:2<375::AID-CNCR2820710218>3.0.CO;2-4","article-title":"Apocrine carcinoma of the skin. A clinicopathologic, immunocytochemical, and ultrastructural study","volume":"71","author":"Paties","year":"1993","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1309\/ajcp2n1afxefovye","article-title":"Immunohistochemical distinction of primary sweat gland carcinoma and metastatic breast carcinoma: can it always be accomplished reliably","volume":"143","author":"Mentrikoski","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpr.2021.300560","article-title":"Primary cutaneous apocrine carcinoma in a 50-year old male","volume":"26","author":"Crabtree","year":"2021","journal-title":"Hum Pathol Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-200410000-00001","article-title":"Primary cutaneous mucinous carcinoma: presence of myoepithelial cells as a clue to the cutaneous origin","volume":"26","author":"Qureshi","year":"2004","journal-title":"Am J Dermatopathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000028808","article-title":"Primary cutaneous apocrine carcinoma of the scalp","volume":"101","author":"Choi","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/9781316576816.004","article-title":"Neoplasms of cutaneous appendages","volume-title":"Immunohistochemistry in Diagnostic Dermatopathology","author":"Hoang","year":"2017"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0594-x","article-title":"Treatment strategy for cutaneous apocrine carcinoma","volume":"19","author":"Ogata","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.12688\/f1000research.135154.3","article-title":"Case report: a pathological odyssey in primary cutaneous apocrine carcinoma","volume":"12","author":"Naseri","year":"2023","journal-title":"F1000Research"},{"key":"B40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1634\/theoncologist.2-1-18","article-title":"Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer","volume":"2","author":"McLeod","year":"1997","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2941","article-title":"Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000110502.10593.06","article-title":"Vascular endothelial growth factor activates PI3K\/akt\/forkhead signaling in endothelial cells","volume":"24","author":"Abid","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.2022.40.16_suppl.2592","article-title":"Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000022913","article-title":"Anti-PD-1 antibody therapy for epithelial skin Malignancies","volume":"99","author":"Ishii","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:38:47Z","timestamp":1784785127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1802283"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1802283","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1802283"}}